Inovio Pharmaceuticals (INO) Other Non-Current Liabilities (2010 - 2022)

Inovio Pharmaceuticals has disclosed Other Non-Current Liabilities across 13 years of filings, most recently posting $710348.0 for Q3 2022.

• In Q3 2022, Other Non-Current Liabilities rose 1007.48% year-over-year to $710348.0; the TTM figure through Sep 2022 stood at $710348.0 (up 1007.48% YoY), while the FY2021 annual figure was $14826.0, down 74.29% from the prior year.
• Other Non-Current Liabilities came in at $710348.0 for Q3 2022 at Inovio Pharmaceuticals, up from $14826.0 in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $119.8 million in Q2 2020 to a low of $14826.0 in Q4 2021.
• Average Other Non-Current Liabilities over 5 years is $9.2 million, with a median of $87333.0 recorded in 2018.
• Year-over-year, Other Non-Current Liabilities soared 235895.43% in 2020 and slumped 99.95% in 2021.
• Over 5 years, Other Non-Current Liabilities stood at $87333.0 in 2018, then surged by 9998.16% to $8.8 million in 2019, then slumped by 99.35% to $57663.0 in 2020, then slumped by 74.29% to $14826.0 in 2021, then surged by 4691.23% to $710348.0 in 2022.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $710348.0 in Q3 2022, $14826.0 in Q4 2021, and $64141.0 in Q3 2021.